SCHEMBL4346840

SCHEMBL4346840

O=C(Nc1cccc(Cl)c1O)Nc1cccc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.63
KDM4E B2RXH2 6/20 0.62
MAPT P10636 2/20 0.62
POLB P06746 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
GRIK1 P39086 1/20 0.57
RAB9A P51151 5/20 0.56
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
GAA P10253 2/20 0.56
GSK3B P49841 1/20 0.54
EPHX1 P07099 1/20 0.52
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NOX1 Q9Y5S8 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350014 0.85 GRIK1 (0.62) TRPV1KDM4EMAPTPOLBSMN1; SMN2
SCHEMBL1276481 0.85 KDM4E (0.82) KDM4EMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL30393282 0.85 KDM4E (0.82) KDM4EMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL4345909 0.84 KDM4E (0.66) TRPV1KDM4EMAPTPOLBSMN1; SMN2
SCHEMBL9407433 0.82 RAB9A (0.58) KDM4EMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL4345368 0.81 RAB9A (0.65) KDM4EMAPTPOLBSMN1; SMN2GRIK1
SCHEMBL4354878 0.81 MEN1 (0.73) TRPV1KDM4EMAPTPOLBSMN1; SMN2
SCHEMBL4348857 0.79 DDX3X (0.59) TRPV1KDM4EMAPTPOLBSMN1; SMN2
SCHEMBL6822942 0.79 CXCR2 (0.73) MAPTGRIK1RAB9AKMT2AMEN1
SCHEMBL3706591 0.79 CXCR2 (0.73) MAPTGRIK1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 TRPV1 2328/4885KDM4E 2662/4885MAPT 4439/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 TRPV1 2320/4885KDM4E 1689/4885MAPT 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.